Page 13 - Caredx News Today

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds CareDx Advertising of AlloSure to be Accurate and Truthful...

Wall Street brokerages expect CareDx, Inc (NASDAQ:CDNA – Get Rating) to report sales of $78.63 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for CareDx’s earnings, with the lowest sales estimate coming in at $76.90 million and the highest estimate coming in at $81.79 million. CareDx posted sales of […]

CareDx Also Hosting Educational Webinar “Innovations in Kidney Care” to Help Improve the Pre- and Post-Transplant Journey for Patients...

Results from CareDx's OKRA Study and Cibiltech's CIBIL Study will Demonstrate Clinical Utility of iBox for Transplant Patient ManagementSOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CareDx

NEW YORK, Feb. 27, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating...

CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney...

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims...

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm is investigating...

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating...

Two AlloSure abstracts will be featured at ASN, and CareDx will showcase innovations in transplantation at a virtual event on November 5...